SCHEMBL5244010

SCHEMBL5244010

COC(=O)c1ccc(C(=O)OC)c(NS(=O)(=O)c2cccc3nonc23)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACLY P53396 1/20 0.60
▸ ALDH1A1 P00352 8/20 0.57
▸ KMT2A Q03164 5/20 0.57
▸ MAPT P10636 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ POLB P06746 2/20 0.56
▸ GFER P55789 1/20 0.56
▸ CCKBR P32239 1/20 0.54
▸ KDM4E B2RXH2 4/20 0.53
▸ HSD17B10 Q99714 3/20 0.53
▸ LMNA P02545 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ HPGD P15428 3/20 0.51
▸ CASP1 P29466 1/20 0.49
▸ CASP7 P55210 1/20 0.49
▸ HTT P42858 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8160125 0.83 ALDH1A1 (0.69) ALDH1A1KMT2AMAPTSMN1; SMN2MEN1
SCHEMBL21999590 0.75 ACLY (1.00) ACLYALDH1A1KMT2AMAPTPOLB
SCHEMBL5245085 0.74 ALDH1A1 (0.58) ALDH1A1KMT2AMAPTSMN1; SMN2MAPK1
SCHEMBL6396298 0.74 ALDH1A1 (0.75) ACLYALDH1A1KMT2AMAPTSMN1; SMN2
SCHEMBL5247934 0.73 CCKBR (0.50) ACLYALDH1A1KMT2AMEN1POLB
SCHEMBL1891772 0.72 CCKBR (0.66) KMT2APOLBCCKBRLMNA
SCHEMBL1884910 0.72 CCKBR (0.66) ALDH1A1POLBCCKBR
SCHEMBL1886147 0.72 CCKBR (0.68) KMT2AMEN1CCKBR
SCHEMBL3746618 0.72 POLB (0.65) ALDH1A1KMT2AMAPTSMN1; SMN2MEN1
SCHEMBL1882759 0.72 CCKBR (0.66) KMT2AMEN1CCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 — — EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 — — WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 — — US claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP ACLY 3193/4885ALDH1A1 2627/4885KMT2A 1303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback